Salvage therapy with protease inhibitor-sparing regimens containing etravirine

被引：0
|
作者：
Bull, L. [1 ]
Bower, M. [1 ]
Nelson, M. [1 ]
机构：
[1] Chelsea & Westminster Hosp, London, England
来源：
HIV MEDICINE | 2013年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [21] Tipranavir: A protease inhibitor for HIV salvage therapy
    Dong, Betty J.
    Cocohoba, Jennifer M.
    [J]. ANNALS OF PHARMACOTHERAPY, 2006, 40 (7-8) : 1311 - 1321
  • [22] Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation
    Lo, A
    Egidi, MF
    Gaber, LW
    Amiri, HS
    Vera, S
    Nezakatgoo, N
    Gaber, AS
    [J]. TRANSPLANTATION, 2004, 77 (08) : 1228 - 1235
  • [23] Steroid or calcineurin inhibitor-sparing immunosuppressive protocols
    Grinyó, JM
    Cruzado, JM
    [J]. KIDNEY TRANSPLANTATION : STRATEGIES TO PREVENT ORGAN REJECTION, 2005, 146 : 30 - 42
  • [24] Evidence for the Immunosuppressive Potential of Calcineurin Inhibitor-Sparing Regimens in Liver Transplant Recipients with Impaired Renal Function
    Tanimine, N.
    Ide, K.
    Tanaka, Y.
    Ishiyama, K.
    Onoe, T.
    Tashiro, H.
    Ohdan, H.
    [J]. TRANSPLANTATION, 2012, 94 (10) : 679 - 679
  • [25] Evidence for the Immunosuppressive Potential of Calcineurin Inhibitor-Sparing Regimens in Liver Transplant Recipients with Impaired Renal Function
    Ide, Kentaro
    Tanaka, Yuka
    Onoe, Takashi
    Banshodani, Masataka
    Tazawa, Hirofumi
    Igarashi, Yuka
    Basnet, Nabin Bahadur
    Doskali, Marlen
    Tashiro, Hirotaka
    Ohdan, Hideki
    [J]. JOURNAL OF TRANSPLANTATION, 2011, 2011
  • [26] Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome
    Gianotti, N
    Soria, A
    Galli, L
    Giudici, B
    Fusetti, G
    Lazzarin, A
    Boeri, E
    Castagna, A
    [J]. AIDS, 2004, 18 (05) : 821 - 823
  • [27] Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy
    Kantor, R
    Fessel, WJ
    Zolopa, AR
    Israelski, D
    Shulman, N
    Montoya, JG
    Harbour, M
    Schapiro, JM
    Shafer, RW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) : 1086 - 1092
  • [28] Steroid and Calcineurin Inhibitor-Sparing Protocols in Kidney Transplantation
    Helal, I.
    Chan, L.
    [J]. TRANSPLANTATION PROCEEDINGS, 2011, 43 (02) : 472 - 477
  • [29] Evolution of human immunodeficiency virus type-1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen
    Gianotti, N
    Seminari, E
    Lazzarin, A
    Boeri, E
    Clementi, M
    Danise, A
    Salpietro, S
    Fusetti, G
    Castagna, A
    [J]. ANTIVIRAL THERAPY, 2004, 9 (04) : U66 - U66
  • [30] Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue
    Karris, Maile Y.
    Jain, Sonia
    Bowman, Vi Q.
    Rieg, Gunter
    Goicoechea, Miguel
    Dube, Michael P.
    Kerkar, Shubha
    Kemper, Carol
    Diamond, Catherine
    Sun, Xiaoying
    Daar, Eric S.
    Haubrich, Richard H.
    Morris, Sheldon
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (02) : E48 - E50
12345